Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 11,544 followers.

RT @jitcancer: New #JITC article: Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pem…

New #JITC article: Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma https://t.co/NyL9xNyYvu @CraigSlingluff…

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma https://t.co/KT3xWMpCwZ https://t.co/4bndgWxu8l

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.